A landmark $16M clinical trial led by Sylvester Comprehensive Cancer Center will assess AI's impact on radiologist performance in mammography screening.
Key Details
- 1PRISM is the first major randomized U.S. trial to study AI in breast cancer screening.
- 2Supported by a $16 million award from PCORI, the study spans hundreds of thousands of mammograms across six states.
- 3Seven academic medical centers, including UCLA and University of Miami, are participating.
- 4The trial uses Transpara by ScreenPoint Medical as the AI tool, integrated via Aidoc aiOS.
- 5Radiologists will remain in control of interpretations, with randomized assignment to AI-assisted or radiologist-only reads.
- 6Outcomes include cancer detection, recall rates, and perceptions of AI from both patients and clinicians.
Why It Matters
This large, multicenter trial could establish high-level evidence on the true value of AI assistance in real-world breast imaging, directly influencing clinical implementation, policy, and practice. Its patient-centered design and rigorous methodology will help clarify how—and for whom—AI can best improve breast cancer screening results.
Source
EurekAlert
Related News
•EurekAlert
New Daydreaming Algorithm Boosts Neural Networks' Recall of Biased Image Data
Researchers unveil a new 'Centered Daydreaming' algorithm enabling AI to effectively learn and recall from imbalanced, real-world image data.
•EurekAlert
Polymer-Based Flexible Wireless Sensors: AI-Driven Health Monitoring Review
A major review highlights how advanced polymer-based flexible wireless sensors, enhanced by AI-driven data processing, can transform continuous physiological health monitoring.
•EurekAlert
PET Imaging Uncovers Synaptic Loss Patterns in Schizophrenia
A major PET imaging study reveals widespread, non-random synaptic loss in schizophrenia, distinct from brain volume changes seen on MRI.